FGFR1 and non-small cell lung carcinoma: Furthermore, in non-small cell lung cancer (NSCLC) cells overexpressing FGFR1, ponatinib demonstrated potent antiproliferative effects, suggesting therapeutic applicability in FGFR1-addicted solid tumors [155].